Roche, a Swiss multinational healthcare company, completed the acquisition of Inflazome, an Ireland-based biotechnology company, from private equity firms Novartis, Forbion Capital Partners, Longitude Capital Management and Fountain Healthcare Partners for €380m ($448m). "We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases," Matt Cooper, Inflazome CEO.